Browsing by Author Colonno, R

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 4 to 13 of 13 < previous 
TitleAuthor(s)Issue DateViews
 
Continued therapy with ABI-H0731+NRTI results in sequential reduction/loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg positive patients
Proceeding/Conference:Hepatology
Sulkowski, MSAgarwal, KFung, SKYuen, RMFMa, XLLalezari, JPNguyen, TTBae, HSSchiff, ERHassanein, THann, HWLElkhashab, MDieterich, DTKwo, PYNahass, RRamji, APark, JSRavendhran, NChan, SWeilert, FHan, SHBAyoub, WSGane, EJJacobson, IMBennett, MBonacini, MZayed, HAlves, KHuey, VHuang, QRuby, EQiang, DMKnox, SColonno, R
2019
10
 
Entecavir (ETV) Results in Higher HBV-DNA Reduction vs Adefovir (ADV) In Chronically Infected HBeAg(+) Antiviral-Naive Adults: 48-Week Results (E.A.R.L.Y. STUDY)
Proceeding/Conference:Digestive Disease Week
Leung, NSherman, MPeng, CYSollano, JDLesmana, LYuen, RMFJeffers, LHann, HWMenearini, KColonno, RCross, AWilber, RLopez-Talavera, JC
2007
63
 
Entecavir (ETV) vs. Adefovir (ADV): HBV DNA reduction of viral load in chronically infected HBeAg(+) nucleoside naive adults in a 12-week
Proceeding/Conference:Journal of clinical virology
Sherman, MHann, HWJeffers, LMin, ALeung, NPeng, CYLiaw, YFSollano, JLesmana, LYuen, RMFZhu, JMencarini, KColonno, RCross, AWilber, RLopez-Talavera, JC
2006
66
 
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
Journal:New England Journal of Medicine
Lai, CLShouval, DLok, ASChang, TTCheinquer, HGoodman, ZDeHertogh, DWilber, RZink, RCCross, AColonno, RFernandes, L
2006
131
 
Final results of a phase 1b 28-day study of ABI-H0731, a novel core inhibitor, in non-cirrhotic viremic subjects with chronic hepatitis B
Journal:Hepatology
Yuen, RMFAgarwal, KGane, EJSchwabe, .CAhn, SHKim, DJLim, YSCheng, WSievert, WVisvanathan, KRuby, ELiaw, SYan, RConnelly, ECai, DWHuang, QColonno, RLopatin, UA
2018
 
Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients
Proceeding/Conference:Journal of Hepatology
Ma, XLLalezari, JNguyuen, TBae, HoSchiff, ERFung, SYuen, RMFHassanein, THann, HWElkhashab, MDieterich, DSulkowski, MKwo, PNahass, RAgarwal, KRamji, APark, JRavendhran, NChan, SWeilert, FHan, SHAyoub, WGane, EJacobson, IBennett, MHuang, QYan, RHuey, VRuby, ELiaw, SColonno, RLopatin, U
2019
2
 
Interim safety, tolerability pharmacokinetics, and antiviral activity of ABI-H0731, a novel core protein allosteric modulator, in healthy volunteers and non-cirrhotic viremic subjects with chronic hepatitis B
Proceeding/Conference:Journal of Hepatology
Yuen, RMFAgarwal, KGane, ESchwabe, CCheng, WSievert, WKim, DJAhn, SHLim, YSVisvanathan, KRuby, ELiaw, SColonno, RLopatin, U
2018
2
 
Long-term follow-up of entecavir treated protocol-defined non responders in rollover study ETV-901
Proceeding/Conference:Hepatology
Sherman, MRizzetto, MLai, CLLiaw, YFGadano, AJacobson, IMSchiff, ERYang, JColonno, RKreter, BHindes, R
2007
69
 
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
Journal:The Lancet Gastroenterology & Hepatology
Yuen, MFAgarwal, KGane, EJSchwabe, CAhn, SHKim, DJLim, YSCheng, WSievert, WVisvanathan, KRuby, ELiaw, SYan, RHuang, QColonno, RLopatin, U
2020
 
The second-generation hepatitis B virus (HBV) core inhibitor (CI) ABI-H2158 is associated with potent antiviral activity in a 14-day monotherapy study in HBeAg-positive patients with chronic hepatitis B (CHB)
Proceeding/Conference:Hepatology
Yuen, RMFAgarwal, KGane, EJNguyen, TTHassanein, TKim, DJAlves, KZayed, HQiang, DMRuby, EEvanchik, MHuang, QKnox, SColonno, Ron behalf of ABI-H2158 Study Team
2019
6
Showing results 4 to 13 of 13 < previous